Precision motion control / force-torque sensing for humanoid and cobot technology and investment research

Technical bottleneck

• Bottleneck type: Qualification friction / integration complexity / medical-grade precision
• Technical constraint: Force/torque sensing accuracy at robot joint; encoder resolution for precision manipulation; drive latency for compliant control algorithms
• Economic constraint: NOVT $257.7M Q1 2026 revenue (+10.4% YoY); bookings +37% YoY; book-to-bill ~1.1; OCF +63%. Not yet humanoid-specific revenue but strong demand signal.

Adoption

• Driver: NVIDIA Halos partnership validates AI robotics stack compatibility; humanoid OEMs sourcing from qualified suppliers; IMS division promoting integrated stepper modules; surgical robotics base provides design-in momentum
• Blocker: No public named humanoid OEM design win confirmed; competition from Maxon Motor (private Switzerland), Faulhaber (private Germany); NOVT premium price vs commodity motors

Product categories

Frameless torque motors, force/torque sensors, optical encoders, integrated servo drives, motion control modules

Public companies exposed

NOVT (Novanta), RRX (Kollmorgen), Maxon (private), Faulhaber (private), MOG.A (high-performance defense-grade)

• AME (AME)

Validation signals

NOVT explicit humanoid OEM design win announcement; robotics segment revenue break-out in earnings; IMS/Celera Motion product roadmap targeting humanoid specs; follow-on NVIDIA Halos platform integrations

Invalidation signals

Commodity motor suppliers win on price; humanoid OEMs vertically integrate motor/drive production; NOVT revenue growth decelerates despite robotics narrative

Related product map rows

• NOVT — Early: Semiconductor innovation → robotics capability → industrial automation → motion control bottleneck → NOVT precision motion+photonics subsystems for robotics/surgical/semi OEMs; servo crunch beneficiar · confidence low
• MOG.A — Emerging: Autonomous system demand → motion control infrastructure → Moog precision actuation systems for defense drones/aerospace/industrial robots; CCA/loyal wingman + C-UAS program beneficiary · confidence low
• NOVT — Precision motion subsystems (servo controllers, motion stages, laser systems) + photonics components (laser scanning, optical components): · confidence high

Research Update — 2026-07-26

_Source: SEC 10-K / 10-Q / EX-99.1 during NOVT backfill_

Technical readiness: deployed and scaling. Novanta's Automation Enabling Technologies segment already sells laser beam steering/scanning, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles to OEMs in advanced industrial, medical robotics, and medical laser applications.

Key papers / sources:

• SEC 10-K 2025 — Automation Enabling Technologies revenue $500.8M, gross margin 47.8%, operating profit $114.5M; Medical Solutions revenue $479.8M, gross margin 41.6%, operating profit $51.2M.
• SEC 10-Q Q1 2026 — total revenue $257.707M; Automation Enabling Technologies $131.244M; Medical Solutions $126.463M.
• SEC EX-99.1 Q1 2026 — bookings +37% YoY and book-to-bill about 1.1x.

Public parameter table:

• FY2025 AET revenue: $500.8M; gross margin: 47.8%; operating margin: 22.9% (derived from $114.5M / $500.8M) [SEC 10-K].
• FY2025 Medical Solutions revenue: $479.8M; gross margin: 41.6%; operating margin: 10.7% (derived from $51.2M / $479.8M) [SEC 10-K].
• Q1 2026 Medical Solutions revenue: $126.463M [SEC 10-Q].
• Q1 2026 book-to-bill: ~1.1x [SEC EX-99.1].

Worked calculation:

• If Medical Solutions merely matched AET's FY2025 gross margin, incremental gross profit would be $479.8M × (47.8% - 41.6%) = $29.7M.
• That uplift equals 6.8% of FY2025 consolidated gross profit and 31.6% of FY2025 consolidated operating income, showing how much value sits in qualified, higher-margin motion/photonics subsystems rather than the base revenue line.

Sensitivity analysis:

• Every 1 percentage-point change in Medical Solutions gross margin changes FY2025 gross profit by about $4.8M.
• A 2-point improvement adds about $9.6M; a 4-point improvement adds about $19.2M.
• At a 1.1x quarterly book-to-bill, Q1 2026 implied orders were about $283.5M, or $25.8M above revenue for the quarter, implying a roughly $103.1M annualized backlog cushion if sustained.

Bottleneck update: unchanged but better quantified. The moat is not a commodity motor; it's the qualification stack that lets Novanta keep its precision motion + photonics content inside OEM programs while preserving margin.

Alternative/substitute risk: vertically integrated OEMs or lower-cost motion suppliers can pressure the lower-margin industrial slice, but the medical/robotics qualification bar keeps the higher-margin slice sticky.

Timeline signal: already monetized. The question is not if the bottleneck exists, but how much of mix can shift into the higher-margin qualified applications over the next 6-24 months.

Adoption rate data: Q1 bookings +37% YoY; book-to-bill ~1.1x; segment revenue in Q1 2026 still split roughly evenly between AET and Medical Solutions, suggesting robotics/automation demand is broadening rather than being a one-off spike.

Thesis impact: this backfill strengthens the thesis by quantifying the margin leverage embedded in qualified motion/photonics mix. The economics are less about headline growth and more about how much of the installed customer base can be moved into higher-margin qualified programs.

Related research

• Sensing & Perception Master Deep Dive — consolidated machine-vision / LiDAR / sensing deep-dive (2026-08-14).